As of 2026-08-17, the EV/EBITDA ratio of Arrowhead Pharmaceuticals Inc (ARWR) is -75.75. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ARWR's latest enterprise value is 13,410.04 mil USD. ARWR's TTM EBITDA according to its financial statements is -177.03 mil USD. Dividing these 2 quantities gives us the above ARWR EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 16.4x | 14.1x |
| Forward P/E multiples | 13.4x - 16.1x | 14.7x |
| Fair Price | (22.86) - 223.33 | 88.71 |
| Upside | -126.4% - 157.8% | 2.4% |
| Date | EV/EBITDA |
| 2026-08-14 | -75.75 |
| 2026-08-13 | -74.92 |
| 2026-08-12 | -76.24 |
| 2026-08-11 | -77.82 |
| 2026-08-10 | -77.10 |
| 2026-08-07 | -76.56 |
| 2026-08-06 | -75.11 |
| 2026-08-05 | -75.97 |
| 2026-08-04 | -78.10 |
| 2026-08-03 | -75.25 |
| 2026-07-31 | -74.17 |
| 2026-07-30 | -76.29 |
| 2026-07-29 | -75.42 |
| 2026-07-28 | -75.07 |
| 2026-07-27 | -74.87 |
| 2026-07-24 | -74.92 |
| 2026-07-23 | -75.86 |
| 2026-07-22 | -77.39 |
| 2026-07-21 | -66.11 |
| 2026-07-20 | -63.82 |
| 2026-07-17 | -65.93 |
| 2026-07-16 | -63.61 |
| 2026-07-15 | -63.96 |
| 2026-07-14 | -64.03 |
| 2026-07-13 | -65.78 |
| 2026-07-10 | -67.60 |
| 2026-07-09 | -73.65 |
| 2026-07-08 | -75.04 |
| 2026-07-07 | -76.01 |
| 2026-07-06 | -75.68 |
| 2026-07-02 | -73.64 |
| 2026-07-01 | -70.82 |
| 2026-06-30 | -71.67 |
| 2026-06-29 | -70.87 |
| 2026-06-26 | -69.59 |
| 2026-06-25 | -69.89 |
| 2026-06-24 | -70.32 |
| 2026-06-23 | -70.39 |
| 2026-06-22 | -72.06 |
| 2026-06-18 | -71.92 |
| 2026-06-17 | -71.30 |
| 2026-06-16 | -67.72 |
| 2026-06-15 | -68.20 |
| 2026-06-12 | -66.11 |
| 2026-06-11 | -66.02 |
| 2026-06-10 | -63.09 |
| 2026-06-09 | -65.16 |
| 2026-06-08 | -65.58 |
| 2026-06-05 | -64.97 |
| 2026-06-04 | -66.62 |